Wall Street equity research analysts tracking Acumen Pharmaceuticals (NASDAQ: ABOS) maintain a consensus rating that leans toward a moderate buy, supported by institutional optimism surrounding its neurological drug development pipeline. Consensus twelve-month price predictions cluster around an average target of $8.00 per share, though individual firm evaluations vary based on upcoming clinical trial catalysts, regulatory updates, and prevailing small-cap biotech market sentiment.